Patient info Open main menu

Micardisplus 40 mg / 12.5 mg tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
40 mg / 12.5 mg
Contains active substances:

Patient leaflet - Micardisplus 40 mg / 12.5 mg tablets

1. What MicardisPlus is and what it is used for

MicardisPlus is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet. Both substances help to control high

blood pressure.

  • Telmisartan belongs to a group of medicines

    called angiotensin II receptor blockers. Angiotensin-II is a substance produced in your body which causes your blood vessels to narrow, thus increasing your blood pressure. Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.

  • Hydrochlorothiazide belongs to a group of

    medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure.

High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus, it is important to regularly measure blood pressure to verify if it is within the normal range.

MicardisPlus is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan is used alone.

2. What you need to know before you take MicardisPlus

Do not take MicardisPlus

  • if you are allergic to telmisartan or any

    of the other ingredients of this medicine (listed in section 6).

  • if you are allergic to hydrochlorothiazide or to

    any other sulfonamide-derived medicines.

  • if you are more than 3 months pregnant.

    (It is also better to avoid MicardisPlus in early pregnancy – see pregnancy section.)

  • if you have severe liver problems such as

    cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.

  • if you have severe kidney disease or anuria

    (less than 100 ml urine per day).

  • if your doctor determines that you have low

    potassium levels or high calcium levels in your blood that do not get better with treatment.

  • if you have diabetes or impaired kidney

    function and you are treated with a blood pressure lowering medicine containing aliskiren.

If any of the above applies to you, tell your doctor or pharmacist before taking MicardisPlus.

Warnings and precautions

Talk to your doctor before taking MicardisPlus if you are suffering or have ever suffered from any of the following conditions or illnesses:

  • Low blood pressure (hypotension), likely to

    occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy (water tablets), low-salt diet, diarrhoea, vomiting, or haemofiltration.

  • Kidney disease or kidney transplant.
  • Renal artery stenosis (narrowing of the blood

    vessels to one or both kidneys).

  • Liver disease.
  • Heart trouble.
  • Diabetes.
  • Gout.
  • Raised aldosterone levels (water and salt

    retention in the body along with imbalance of various blood minerals).

  • Systemic lupus erythematosus (also called

    “lupus” or “SLE”) a disease where the body’s immune system attacks the body.

    • The active ingredient hydrochlorothiazide

      can cause an unusual reaction, resulting in a decrease in vision and eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking MicardisPlus. This can lead to permanent vision impairment, if not treated.

    • If you have had skin cancer or if you develop an

      unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly

      long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking MicardisPlus.

Talk to your doctor before taking MicardisPlus:

  • if you are taking any of the following medicines

    used to treat high blood pressure:

    • an ACE-inhibitor (for example enalapril,

      lisinopril, ramipril), in particular if you have diabetes-related kidney problems.

    • aliskiren.

Your doctor may check your kidney function,

blood pressure, and the amount of electrolytes

(e.g. potassium) in your blood at regular intervals. See also information under the heading “Do not take MicardisPlus”.

  • if you are taking digoxin.
  • if you experienced breathing or lung problems

    (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past. If you develop any severe shortness of breath or difficulty breathing after taking MicardisPlus, seek medical attention immediately.

Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking MicardisPlus. Your doctor will decide on further treatment. Do not stop taking MicardisPlus on your own.

You must tell your doctor if you think you are (or might become) pregnant. MicardisPlus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).

Treatment with hydrochlorothiazide may cause electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, nausea (feeling sick), vomiting, tired muscles, and an abnormally fast heart rate (faster than 100 beats

per minute). If you experience any of these you should tell your doctor.

You should also tell your doctor, if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal.

In case of surgery or anaesthetics, you should tell your doctor that you are taking MicardisPlus.

MicardisPlus may be less effective in lowering the blood pressure in black patients.

Children and adolescents

The use of MicardisPlus in children and adolescents up to the age of 18 years is not recommended.

Other medicines and MicardisPlus

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change the dose of these other medications or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same

time with MicardisPlus:

  • Lithium containing medicines to treat some

    types of depression.

  • Medicines associated with low blood

    potassium (hypokalaemia) such as other diuretics, (‘water tablets’), laxatives

    (e.g. castor oil), corticosteroids (e.g. prednisone), ACTH (a hormone), amphotericin (an antifungal medicine), carbenoxolone (used to treat mouth ulcers), penicillin G sodium (an antibiotic), and salicylic acid and derivatives.

  • Iodinated contrast product used in the context

    of an imaging examination.

  • Medicines that may increase blood potassium

    levels such as potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, ACE inhibitors, cyclosporin (an immunosuppressant medicine) and other medicinal products such as heparin sodium (an anticoagulant).

  • Medicines that are affected by changes of

    the blood potassium level such as heart medicines (e.g. digoxin) or medicines to control the rhythm of your heart (e.g. quinidine, disopyramide, amiodarone, sotalol), medicines used for mental disorders (e.g. thioridazine, chlorpromazine, levomepromazine) and other medicines such as certain antibiotics

    (e.g. sparfloxacine, pentamidine) or certain medicines to treat allergic reactions (e.g. terfenadine).

  • Medicines for the treatment of diabetes

    (insulins or oral agents such as metformin).

  • Cholestyramine and colestipol, medicines for

    lowering blood fat levels.

  • Medicines to increase blood pressure, such as

    noradrenaline.

  • Muscle relaxing medicines, such as

    tubocurarine.

  • Calcium supplements and/or vitamin

    D supplements.

  • Anti-cholinergic medicines (medicines

    used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson’s disease and as an aid to anaesthesia) such as atropine and biperiden.

  • Amantadine (medicine used to treat Parkinson’s

    disease and also used to treat or prevent certain illnesses caused by viruses).

  • Other medicines used to treat high blood

    pressure, corticosteroids, painkillers (such as non-steroidal anti-inflammatory drugs [NSAIDs]), medicines to treat cancer, gout, or arthritis.

    • If you are taking an ACE-inhibitor or

      aliskiren (see also information under the headings “Do not take MicardisPlus” and “Warnings and precautions”).

    • Digoxin.

MicardisPlus may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or

antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking MicardisPlus.

The effect of MicardisPlus may be reduced when you take NSAIDs (non-steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).

MicardisPlus with food and alcohol

You can take MicardisPlus with or without food. Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint.

Pregnancy and breast-feeding

Pregnancy

You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking MicardisPlus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of MicardisPlus. MicardisPlus is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding

Tell your doctor if you are breast-feeding or about to start breast-feeding. MicardisPlus is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.

Driving and using machines

Some people feel dizzy, faint or feel like everything around you is spinning when taking MicardisPlus. If you experience any of these effects, do not drive or operate machinery.

MicardisPlus contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

MicardisPlus contains milk sugar (lactose)

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

MicardisPlus contains sorbitol

This medicine contains 169 mg sorbitol in each tablet.

3. How to take MicardisPlus

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is one tablet a day. Try to take the tablet at the same time each day. You can take MicardisPlus with or without food. The tablets should be swallowed whole with some water or other non-alcoholic drink. It is important that you take MicardisPlus every day until your doctor tells you otherwise.

If your liver is not working properly, the usual dose should not exceed 40 mg telmisartan once a day.

If you take more MicardisPlus than you should

If you accidentally take too many tablets you may experience symptoms such as low blood pressure and rapid heartbeat. Slow heartbeat, dizziness, vomiting, reduced kidney function including kidney failure, have also been reported. Due to the hydrochlorothiazide component, markedly low blood pressure and low blood levels of potassium can also happen, which may result in nausea, sleepiness and muscle cramps and/or irregular heartbeat associated with the concomitant use of medicines such as digitalis or certain anti-arrhythmic treatments. Contact your doctor, pharmacist, or your nearest hospital emergency department immediately.

If you forget to take MicardisPlus

If you forget to take a dose, do not worry. Take it as soon as you remember then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses.

If you have further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects can be serious and need immediate medical attention:

You should see your doctor immediately if you experience any of the following symptoms:

Sepsis* (often called “blood poisoning”), is a severe infection with whole-body inflammatory response, rapid swelling of the skin and mucosa (angioedema including fatal outcome), blistering and peeling of the top layer of skin (toxic epidermal necrolysis); these side effects are rare (may affect up to 1 in 1 000 people) or very rare (toxic epidermal necrolysis; may affect up to 1 in 10 000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.

If these effects are not treated they could be fatal. Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for MicardisPlus.

Package leaflet: Information for the user

MicardisPlus® abcd 40 mg/12.5 mg

tablets

telmisartan/hydrochlorothiazide

MicardisPlus® 40 mg/12.5 mg tablets

telmisartan/hydrochlorothiazide

abcd

MicardisPlus®

40 mg/12.5 mg

tablets

telmisartan/hydrochlorothiazide

abcd

Additional requirements of Packaging site
Template name: BI_PI_595x270_85x55Version: 06
Dimensions: 595 x 270 mm unfolded
Rottendorf Pharma GmbHTypopharma No. #107970
Norm SP-140053-001-BPDF 1.3, Indesing cc 2021

G

J

D E

Example:

control code type:

In-process control code specification

MASS D 0,5 mm

MASS E 1,5 mm

MASS G 1,0 mm

MASS F >10,0 mm

File information
Issue date of TD:

Perigord No: 880151 P2

Mandatory in
TDPrintfile
19/July/2021YesYes
PPM SKU: P053586NoYes
PPM SKU version: 005NoYes
NoYes
Print colors: PAN BLACKNoYes
Mat. No. Pack. Site: 321532NoYes

Possible side effects of MicardisPlus:

Common side effects (may affect up to 1 in 10 people)

Dizziness.

Uncommon side effects (may affect up to 1 in 100 people)

Decreased blood potassium levels, anxiety, fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels.

Rare side effects (may affect up to 1 in 1 000 people)

Inflammation of the airways to the lungs (bronchitis), sore throat, inflamed sinuses, increased level of uric acid, low sodium level, feeling sad (depression), difficulty falling asleep (insomnia), sleep disorder, impaired vision, blurred vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities (leg pain), muscle cramps, activation or worsening of systemic lupus erythematosus (a disease where the body’s immune system attacks the body, which causes joint pain, skin rashes and fever), flu-like illness, pain, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood.

Adverse reactions reported with one of the individual components may be potential adverse reactions with MicardisPlus, even if not observed in clinical trials with this product.

Telmisartan

In patients taking telmisartan alone the following additional side effects have been reported:

Uncommon side effects (may affect up to 1 in 100 people)

Upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), urinary tract infections, infection of urinary bladder, deficiency in red blood cells (anaemia), high potassium levels, slow heart rate (bradycardia), cough, kidney impairment including acute kidney failure, weakness.

Rare side effects (may affect up to 1 in 1 000 people)

Low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), serious allergic reaction (e.g. hypersensitivity, anaphylactic reaction), low blood sugar levels (in diabetic patients), somnolence, upset stomach, eczema (a skin disorder), drug eruption, toxic skin eruption, tendon pain (tendonitis-like symptoms), decreased haemoglobin (a blood protein).

Very rare side effects (may affect up to 1 in 10 000 people)

Progressive scarring of lung tissue (interstitial lung disease)**

Not known (frequency cannot be estimated from the available data)

Intestinal angioedema: a swelling in the gut presenting with symptoms like abdominal pain, nausea, vomiting, and diarrhoea has been reported after the use of similar products.

* The event may have happened by chance or could be related to a mechanism currently not known.

** Cases of progressive scarring of lung tissue have been reported during intake of telmisartan. However, it is not known whether telmisartan was the cause.

Hydrochlorothiazide

In patients taking hydrochlorothiazide alone the following additional side effects have been reported:

Very common side effects (may affect more than 1 in 10 people)

Elevated blood fat levels.

Common side effects (may affect up to 1 in 10 people)

Feeling sick (nausea), low blood magnesium level, decreased appetite.

Uncommon side effects (may affect up to 1 in 100 people)

Acute kidney failure.

Rare side effects (may affect up to 1 in 1 000 people)

Low platelet count (thrombocytopenia), which increases risk of bleeding or bruising (small purple-red marks in skin or other tissue caused by bleeding), high blood calcium level, high blood sugar level, headache, abdominal discomfort, yellowing of the skin or eyes (jaundice), excess of biliary substances in the blood (cholestasis), photosensitivity reaction, uncontrolled blood levels of glucose in patients with a diagnosis of diabetes mellitus, sugars in the urine (glucosuria).

Very rare side effects (may affect up to 1 in 10 000 people)

Abnormal breakdown of red blood cells (haemolytic anaemia), inability of the bone marrow to work properly, reduction of white blood cells (leukopenia, agranulocytosis), serious allergic reactions (e.g. hypersensitivity), increased pH due to low blood chloride level (disturbed acid-base balance, alkalosis hypochloraemic), acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion), inflammation of the pancreas, lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body’s immune system attacks the body), inflammation of blood vessels (vasculitis necrotising).

Not known (frequency cannot be estimated from the available data)

Skin and lip cancer (non-melanoma skin cancer), blood cell deficiency (aplastic anaemia), decrease in vision and eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute-angle closure glaucoma), skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, rash, redness of the skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney impairment.

Low levels of sodium accompanied by symptoms relating to the brain or nerves (feeling sick, progressive disorientation, lack of interest or energy) occurs in isolated cases.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

5. How to store MicardisPlus

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.

This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture. Remove your MicardisPlus tablet from the sealed blister only directly prior to intake.

Occasionally, the outer layer of the blister pack separates from the inner layer between the blister pockets. You do not need to take any action if this happens.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What MicardisPlus contains

  • The active substances are telmisartan and hydrochlorothiazide.

    Each tablet contains 40 mg telmisartan and

    12.5 mg hydrochlorothiazide.

  • The other ingredients are lactose monohydrate, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone K25, red iron oxide (E172), sodium hydroxide, sodium starch glycollate (type A), sorbitol (E420).

What MicardisPlus looks like and contents of the pack

MicardisPlus 40 mg/12.5 mg tablets are red and white, oblong-shaped, two-layer tablets engraved with the company logo and the code ‘H4’. MicardisPlus is available in blister packs containing 14, 28, 56, 84, or 98 tablets, or unit dose blister packs containing 28 × 1, 30 × 1 or 90 × 1 tablets.

Not all pack sizes may be available in your country.

Marketing Authorisation Holder

Boehringer Ingelheim International GmbH Binger Str. 173

55216 Ingelheim am Rhein

Germany

Manufacturer

Rottendorf Pharma GmbH

Ostenfelder Strasse 51 - 61

59320 Ennigerloh

Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom

Boehringer Ingelheim Ltd.

Tel: +44 1344 424 600

This leaflet was last revised in 05/2025.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 14598/0201

Last revision stated in the text: May 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Micardisplus 40 mg / 12.5 mg tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substances Telmisartan, Hydrochlorothiazide
Strength 40 mg / 12.5 mg
Pharmaceutical form Oral tablet
Red and white oblong shaped two layer tablet of 5.2 mm engraved with the company logo and the code ‘H4’.
How is it taken Oral
Excipients Lactose monohydrate, Magnesium stearate, Maize starch, Meglumine, Microcrystalline cellulose, Povidone (K25), Red ferric oxide (E172), Sodium hydroxide, Sodium starch glycollate (type A), Sorbitol (E420).
Pack sizes 28 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.
Drug group (ATC) Angiotensin II receptor blockers (ARBs) and diuretics
  1. C Cardiovascular system drugs
    1. C09 Agents acting on the renin-angiotensin system
      1. C09D Angiotensin II receptor blockers (ARBs), combinations
        1. C09DA Angiotensin II receptor blockers (ARBs) and diuretics
          1. C09DA07 telmisartan and diuretics
Marketing authorisation PLGB 14598/0201 (first authorised 1 January 2021)
Marketing authorisation holder Boehringer Ingelheim International GmbH
Codes GTIN 5012816099562 · BNF 02050502

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.